Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 927-248-0 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: dermal
Administrative data
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 14 September 1998 - 02 October 1998
- Reliability:
- 1 (reliable without restriction)
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 998
- Report date:
- 1998
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.3 (Acute Toxicity (Dermal))
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- fixed dose procedure
- Limit test:
- yes
Test material
- Reference substance name:
- 6-(1-bromoethyl)-4-chloro-5-fluoropyrimidine
- Cas Number:
- 188416-28-6
- Molecular formula:
- C6H5BrClFN2
- IUPAC Name:
- 6-(1-bromoethyl)-4-chloro-5-fluoropyrimidine
- Test material form:
- liquid
- Details on test material:
- Amber Oil
Constituent 1
- Specific details on test material used for the study:
- Amber to yellow liquid (5494/96/1)
Test animals
- Species:
- rat
- Strain:
- CD-1
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Animals were in the weight range of 2.37 to 268 g and approximately eight E0 eleven weeks of age prior to dosing (Day 1). All the rats were acclimatised to the experimental environment fOr a minimum period of five days prior to the start of the study,
The rats were allocated without conscious bias to ca ges (RS Biotech Sub-Dividable Rodent Cage - polished stainless steel, 20cm high x 39cm wide x 39cm long). The cages -were fitted with grid floors to ensure rapid removal of waste material to undeitrays which were cleaned as necessary. No more than five animals of the same sex were accommodated in each cage. The day prior to dosing and f011owing removal of hair from the treatment site, the animals wereseparated and individually housed. This measure was taken to inhibit cagemates disturbing each others dressings during the treatment period. The animals were not returned to group housing because it was considered skin reactions were too severe.
Administration / exposure
- Type of coverage:
- occlusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- One day prior to treatment., hair was removed from the dorso-lumbar region of each rat with electric clippers taking case to avoid darni*13g the skin, exposing anarea equivalent to approxiniatcl y 10°0 of the total body surface area.
The test substance was applied by spreading it evenly over the prepared skin. The treatment area (approximately .50 ram N 50 mm) was covered with porous gauze held in place with a non irritating dressing, and further covered bv a ,Nitterproof dressing encircled firmly around the trunk of the animal.
Treatment in this manner was perfOrmed on Day l (day of dosing) of the study only - Duration of exposure:
- 2.4 hours exposure period
- Doses:
- 2000 mg/kg
- No. of animals per sex per dose:
- five males and five females
- Control animals:
- no
Results and discussion
Effect levels
- Sex:
- male/female
- Dose descriptor:
- approximate LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- There were no deaths in ay animal throughout the study following a single dermal application of UK 134,821 to a group of ten rats (five males and five females) at a dose level of 2000 mg/kg body weight.
- Clinical signs:
- other: Clinical signs of reaction to treatment characterised b y piloerection, hunched posture, waddling/unsteady and and increased sensitivity to touch. were seen in allrats. Also observed in one or more animals were abnormal respiration, pallid extremities, wa
- Gross pathology:
- No macroscopic) abnormalities were observed tbr animals killed at study termination on Day 29.
Applicant's summary and conclusion
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- There \Nere no deaths ni am animal throughout the study following a single dermal application of UK 134,821 to a group of ten rats (five males and five females) at a dose level of 2000 mg/kg
- Executive summary:
A group of ten fasted rats (five males and five females) received a single topical application of the test substance administered, as supplied, at a dosage of 2000 ing/kp-, bodyweight (EEC and OECD limit dosage), All animals were killed as scheduled at study termination (Day 29) and subjected to a macroscopic examination. Clinical signs of miction to treatment characterised by piloerection, hunched posture, waddling/unsteady gait and increased sensitivity to touch, were seen in all rats. Also observed in one or more animals were abnormal respiration, pallid extremities, walking on toes, abnormal faeces, thin appearance, ungroomed appearance and protruding eyes. Recovery was complete in all instances by Day 25. Application to the skin of UK-134,821 resulted in a considerable level of dermal injury. This was first evident in ail ten rats immediately following removal of the dressings with a similar level of response persistent over the following days and weeks. To assist in identifying when reversibility of tile skin lesions might be anticipated the observation period was extended beyond the scheduled termination (Day 15). By Day 29, reactions had lessened sufficiently to indicate recovery was taking place and a decision was then taken to terminate the study. A notably low bodyweight gain was evident in one male (No 1 on Day 8) and two females (No 6 on Day 15 and No 7 on Day 8). A slight bod:yweight loss was noted in two females (No 8 on Day 8 and No 9 on Day 22). All remaining animals were considered to have achieved satisfactory bodyweight cams throughout the study. With the exception of the dermal lesions, there was no macroscopic abnormalities observed for animals killed at study termination on Day 29. The acute lethal dermal dose to rats of UK-134,821 was demonstrated to be greater than 2000 mg/kg bodyweight.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.